Nkarta (NKTX) Capital Expenditures (2019 - 2026)
Nkarta (NKTX) posted quarterly Capital Expenditures of $413000.0 for Q1 2026, down 20.27% year-over-year from $518000.0 in Q1 2025, and down 26.25% quarter-over-quarter from $560000.0 in Q4 2025.
Nkarta (NKTX) Capital Expenditures (2019 - 2026) Analysis & Trends
Nkarta's Capital Expenditures history runs 8 years deep, the most recent figure standing at $413000.0 for Q1 2026.
- In Q1 2026, Capital Expenditures fell 20.27% year-over-year to $413000.0; the TTM figure through Mar 2026 stood at $1.1 million (down 76.79% YoY), while the FY2025 annual figure was $1.2 million, down 72.6% from the prior year.
- Capital Expenditures for Q1 2026 stood at $413000.0, down from $560000.0 in the prior quarter.
- The five-year high for Capital Expenditures was $35.0 million in Q4 2022, with the low at -$8000.0 in Q3 2025.
- The 5-year median for Capital Expenditures is $1.8 million (2022), against an average of $4.8 million.
- The sharpest annual moves came in 2022 and 2025: Capital Expenditures soared 3105.67% in 2022, then plunged 101.03% in 2025.
- Nkarta's Capital Expenditures stood at $35.0 million in 2022, then plunged by 80.57% to $6.8 million in 2023, then sank by 83.8% to $1.1 million in 2024, then plunged by 49.23% to $560000.0 in 2025, then decreased by 26.25% to $413000.0 in 2026.
- Business Quant data shows NKTX's Capital Expenditures at $413000.0 in Q1 2026, $560000.0 in Q4 2025, and -$8000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 112.20 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 240.20 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 25.02 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 34.68 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -73.57 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 6.26 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 251.02 Mn |
| 10 | Nkarta | 201.14 Mn | 201.14 Mn | - | 183,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 183,000.00 |
| Jun 30, 2026 | 183,000.00 |
| Mar 31, 2026 | 413,000.00 |
| Mar 31, 2026 | 413,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Dec 31, 2025 | 560,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Sep 30, 2025 | -8,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Jun 30, 2025 | 138,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Mar 31, 2025 | 518,000.00 |
| Dec 31, 2024 | 1.10 Mn |
| Dec 31, 2024 | 1.10 Mn |
| Sep 30, 2024 | 777,000.00 |
| Sep 30, 2024 | 777,000.00 |
| Jun 30, 2024 | 2.35 Mn |
| Jun 30, 2024 | 2.35 Mn |
| Mar 31, 2024 | 175,000.00 |
| Mar 31, 2024 | 175,000.00 |